Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics:

• Overview of small cell lung cancer (SCLC) (0:00)
• First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50)
• Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36)
• Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46)
• Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21)

CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics:

• Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
• Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
• Considerations with maintenance therapy for ES-SCLC (9:31)
• Considerations with immunotherapy for ES-SCLC (13:12)
• Curability of SCLC with systemic therapy (15:17)
• Data with chemoimmunotherapy for patients with poor performance status (25:55)
• Future developments in therapy for SCLC (30:11)
• Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:

• Introduction (0:00)
• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
• Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16)
• Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O'Malley (1:00:31)

CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)
• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)
• Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
• Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)
• Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)
• Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)
• Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)

CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:

• Introduction (0:00)
• Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
• Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
• CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
• Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
• Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)

CME information and select publications

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics:

• Introduction (0:00)
• Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27)
• Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05)

CME information and select publications